Spruce Biosciences, Inc. (SPRB)
SPRB Stock Price Chart
Explore Spruce Biosciences, Inc. interactive price chart. Choose custom timeframes to analyze SPRB price movements and trends.
SPRB Company Profile
Discover essential business fundamentals and corporate details for Spruce Biosciences, Inc. (SPRB) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
9 Oct 2020
Employees
20.00
CEO
Javier Szwarcberg
Description
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.
SPRB Financial Timeline
Browse a chronological timeline of Spruce Biosciences, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 May 2026
Upcoming earnings on 10 Nov 2025
Earnings released on 11 Aug 2025
EPS came in at -$3.41 surpassing the estimated -$19.17 by +82.22%.
Stock split effective on 5 Aug 2025
Shares were split 1 : 75 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 15 Apr 2025
EPS came in at -$0.57 falling short of the estimated -$0.21 by -171.43%, while revenue for the quarter reached $700.00K , beating expectations by +180.00%.
Earnings released on 26 Mar 2025
EPS came in at -$0.57 falling short of the estimated -$0.24 by -137.88%, while revenue for the quarter reached $697.00K , missing expectations by -21.24%.
Earnings released on 11 Nov 2024
EPS came in at -$0.21 surpassing the estimated -$0.27 by +22.22%, while revenue for the quarter reached $602.00K , beating expectations by +80.60%.
Earnings released on 12 Aug 2024
EPS came in at -$0.22 surpassing the estimated -$0.33 by +33.33%, while revenue for the quarter reached $1.61M , beating expectations by +8.05%.
Earnings released on 13 May 2024
EPS came in at -$0.28 surpassing the estimated -$0.32 by +12.50%, while revenue for the quarter reached $2.00M , beating expectations by +72.59%.
Earnings released on 13 Mar 2024
EPS came in at -$0.23 surpassing the estimated -$0.41 by +43.90%, while revenue for the quarter reached $2.89M , beating expectations by +106.21%.
Earnings released on 13 Nov 2023
EPS came in at -$0.30 surpassing the estimated -$0.34 by +11.76%, while revenue for the quarter reached $3.07M , beating expectations by +136.38%.
Earnings released on 14 Aug 2023
EPS came in at -$0.32 surpassing the estimated -$0.37 by +13.51%, while revenue for the quarter reached $2.17M , beating expectations by +164.02%.
Earnings released on 15 May 2023
EPS came in at -$0.40 surpassing the estimated -$0.42 by +4.76%, while revenue for the quarter reached $1.96M , beating expectations by +292.80%.
Earnings released on 16 Mar 2023
EPS came in at -$0.47 surpassing the estimated -$0.55 by +14.55%.
Earnings released on 10 Nov 2022
EPS came in at -$0.48 surpassing the estimated -$0.54 by +11.11%.
Earnings released on 10 Aug 2022
EPS came in at -$0.51 surpassing the estimated -$0.54 by +5.56%.
Earnings released on 11 May 2022
EPS came in at -$0.50 falling short of the estimated -$0.45 by -11.11%.
Earnings released on 14 Mar 2022
EPS came in at -$0.39 surpassing the estimated -$0.57 by +31.58%.
Earnings released on 15 Nov 2021
EPS came in at -$0.49 surpassing the estimated -$0.57 by +14.04%.
Earnings released on 10 Aug 2021
EPS came in at -$0.50 falling short of the estimated -$0.45 by -11.11%.
Earnings released on 12 May 2021
EPS came in at -$0.42 surpassing the estimated -$0.44 by +4.55%.
Earnings released on 22 Mar 2021
EPS came in at -$0.39 surpassing the estimated -$0.60 by +35.00%.
Earnings released on 18 Nov 2020
EPS came in at -$12.35 falling short of the estimated -$0.51 by -2.32K%.
Earnings released on 9 Oct 2020
EPS came in at -$0.30 .
SPRB Stock Performance
Access detailed SPRB performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.